Document is current
Any future updates will be listed below
-
Authors
Pilati, Camilla https://orcid.org/0000-0002-1781-5180
Laurent-Puig, Pierre https://orcid.org/0000-0001-8475-5459
- License Information
-
More Information
Article History
Received: 10 October 2025
Revised: 20 October 2025
Accepted: 22 October 2025
First Online: 10 November 2025
Disclosure and competing interests statement
: PL-P has received honoraria for participation in advisory boards and for conference presentations from Merck, Amgen, Bristol Myers Squibb (BMS), Biocartis, Pierre Fabre, and Servier. PL-P is the founder and holds equity in MethysDX. He is also the inventor of a patent concerning the use of miR-31 as a predictive biomarker for response to anti-EGFR therapy.
